AU2007275561B2 - Improvement of arginase levels/activity - Google Patents

Improvement of arginase levels/activity Download PDF

Info

Publication number
AU2007275561B2
AU2007275561B2 AU2007275561A AU2007275561A AU2007275561B2 AU 2007275561 B2 AU2007275561 B2 AU 2007275561B2 AU 2007275561 A AU2007275561 A AU 2007275561A AU 2007275561 A AU2007275561 A AU 2007275561A AU 2007275561 B2 AU2007275561 B2 AU 2007275561B2
Authority
AU
Australia
Prior art keywords
epicatechin
cocoa
derivative
arginase
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007275561A
Other languages
English (en)
Other versions
AU2007275561A1 (en
Inventor
Catherine L. Kwik-Uribe
Harold H. Schmitz
Hagen Schroeter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mars Inc
University of California San Diego UCSD
Original Assignee
Mars Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc, University of California Berkeley, University of California San Diego UCSD filed Critical Mars Inc
Publication of AU2007275561A1 publication Critical patent/AU2007275561A1/en
Application granted granted Critical
Publication of AU2007275561B2 publication Critical patent/AU2007275561B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007275561A 2006-07-21 2007-07-20 Improvement of arginase levels/activity Active AU2007275561B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83268406P 2006-07-21 2006-07-21
US60/832,684 2006-07-21
PCT/US2007/016504 WO2008011173A2 (en) 2006-07-21 2007-07-20 Improvement of arginase levels/activity

Publications (2)

Publication Number Publication Date
AU2007275561A1 AU2007275561A1 (en) 2008-01-24
AU2007275561B2 true AU2007275561B2 (en) 2013-12-19

Family

ID=38957417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007275561A Active AU2007275561B2 (en) 2006-07-21 2007-07-20 Improvement of arginase levels/activity

Country Status (9)

Country Link
US (3) US20080021097A1 (enExample)
EP (2) EP2068941A4 (enExample)
JP (1) JP2010500973A (enExample)
CN (1) CN101516407B (enExample)
AU (1) AU2007275561B2 (enExample)
CA (1) CA2657915A1 (enExample)
IL (1) IL196480A0 (enExample)
RU (2) RU2469742C2 (enExample)
WO (1) WO2008011173A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010236169A1 (en) * 2009-04-17 2011-11-10 Cardero Therapeutics, Inc. Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function
FR2973234A1 (fr) * 2011-03-31 2012-10-05 Oreal Utilisation cosmetique d'inhibiteur d'arginase, comme agent pour freiner la chute des cheveux, des sourcils et/ou des cils
JP2014521702A (ja) * 2011-08-05 2014-08-28 カーデロ セラピューティクス インコーポレイテッド フラボノイド化合物
US9266260B2 (en) * 2011-12-20 2016-02-23 Massachusetts Institute Of Technology Precision continuous stamp casting method for roll-based soft lithography
CN104582699B (zh) * 2012-08-07 2019-10-22 英德斯生物技术私营有限公司 控制糖尿病足溃疡、压迫性溃疡、静脉性下肢溃疡和相关并发症的方法
US11229685B2 (en) 2013-01-29 2022-01-25 Case Western Reserve University Fungal iron acquisition inhibitors and uses thereof
WO2016046375A1 (en) * 2014-09-25 2016-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Theobroma cacao extract for use in the treatment or prevention of receptor tyrosine kinases related disorders
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury
JP6884705B2 (ja) * 2015-11-18 2021-06-09 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット、アルギナーゼ関連疾患検出キット、及びアルギナーゼの阻害剤又は活性剤のスクリーニング方法
WO2017085947A1 (ja) * 2015-11-18 2017-05-26 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット及びアルギナーゼ関連疾患検出キット
WO2017086421A1 (ja) * 2015-11-18 2017-05-26 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット、アルギナーゼ関連疾患検出キット、及びアルギナーゼの阻害剤又は活性剤のスクリーニング方法
JP6925163B2 (ja) * 2017-05-16 2021-08-25 東京応化工業株式会社 尿素の測定方法及び尿素検出キット
CN107815370A (zh) * 2017-11-17 2018-03-20 华坪县腾辉酒业有限公司 一种蓝莓露酒及其制备方法
US11269896B2 (en) 2019-09-10 2022-03-08 Fujitsu Limited System and method for automatic difficulty level estimation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072265A1 (en) * 1999-07-20 2001-01-31 MEDIS S.r.l. Medical Infusion Systems Use of plant polyphenols for treating iron overload
US6469053B1 (en) * 1996-04-02 2002-10-22 Mars Incorporated Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response
US6670390B1 (en) * 1996-04-02 2003-12-30 Mars Incorporated Cocoa extract compounds and methods for making and using the same
US6805883B2 (en) * 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
WO2005123096A2 (en) * 2004-06-14 2005-12-29 Mars, Incorporated Compositions and methods of use of dimer digallates
WO2006049258A1 (ja) * 2004-11-04 2006-05-11 University Of Tsukuba 発酵茶から抽出された高分子ポリフェノール、ミトコンドリア病治療剤、糖尿病予防・治療剤、並びに飲食物
AU2007321019A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554645A (en) 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
US6312753B1 (en) 1996-09-06 2001-11-06 Mars, Incorporated Cocoa components, edible products having enriched polyphenol content, methods of making same and medical uses
US6015913A (en) 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans
US6207842B1 (en) 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
CA2305703A1 (en) * 1997-10-10 1999-04-22 David W. Christianson Compositions and methods for inhibiting arginase activity
PL342857A1 (en) * 1998-03-12 2001-07-16 Mars Inc Products containing polyphenol(s) and l-arginine to stimulate nitric oxide production
US6156912A (en) 1999-04-09 2000-12-05 Mars, Incorporated 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation
US7015338B1 (en) 1999-04-15 2006-03-21 Mars Incorporated Synthetic methods for preparing procyanidin oligomers
JP2001013453A (ja) * 1999-06-28 2001-01-19 Canon Inc 光学装置
JP4112764B2 (ja) * 1999-11-19 2008-07-02 株式会社伊勢半 皮膚外用剤
US6627232B1 (en) 2000-06-09 2003-09-30 Mars Incorporated Method for extracting cocoa procyanidins
CA2463624A1 (en) * 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US20040115285A1 (en) * 2002-12-13 2004-06-17 Peter Rohdewald Method of normalizing glucose levels in blood of patients with diabetes mellitus by oral administration of proanthocyanidins containing plant extracts
US20060293258A1 (en) * 2005-06-23 2006-12-28 Peter Rohdewald Method and composition to treat skin ulcers
AU2006263561A1 (en) * 2005-06-28 2007-01-04 Mars, Incorporated Compositions and methods of use of derivatized flavanols
JP2009501161A (ja) * 2005-06-29 2009-01-15 マース インコーポレーテッド 血管系の健康改善に有用な熱処理されたカカオ製品

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469053B1 (en) * 1996-04-02 2002-10-22 Mars Incorporated Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response
US6670390B1 (en) * 1996-04-02 2003-12-30 Mars Incorporated Cocoa extract compounds and methods for making and using the same
US20050085431A1 (en) * 1996-04-02 2005-04-21 Mars, Incorporated Treatment of hypertension
US6805883B2 (en) * 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
EP1072265A1 (en) * 1999-07-20 2001-01-31 MEDIS S.r.l. Medical Infusion Systems Use of plant polyphenols for treating iron overload
WO2005123096A2 (en) * 2004-06-14 2005-12-29 Mars, Incorporated Compositions and methods of use of dimer digallates
WO2006049258A1 (ja) * 2004-11-04 2006-05-11 University Of Tsukuba 発酵茶から抽出された高分子ポリフェノール、ミトコンドリア病治療剤、糖尿病予防・治療剤、並びに飲食物
AU2007321019A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Kapoor, M. et al. "Effects of Epicatechin Gallate on Wound Healing and Scar Formation in a Full Thickness Incisional Wound Healing Model in Rats" American Journal of Pathology (2004) Vol.165 No.1 pages 299 to 307 *
Schroeter, H. Et al. "(-)-Epicatechin mediates beneficial effects of flavonol-rich cocoa on vascular function in humans" PNAS (2006) Vol.103 No.4 pages 1024-1029 *
Xu, W. t al. "Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension" The FASEB Journal (2004) Vol.18 pages 1746-1748 *
Zhu, Q.Y. et al. "Influence of cocoa flavonols and procyanidins on free radical-induced human erythrocyte hemolysis" Clinical & Developmental Immunology (2005) Vol.12 Nol.1 pages 27 to 34 *

Also Published As

Publication number Publication date
US20080021097A1 (en) 2008-01-24
CN101516407A (zh) 2009-08-26
CN101516407B (zh) 2012-03-21
JP2010500973A (ja) 2010-01-14
US20110257119A1 (en) 2011-10-20
WO2008011173A3 (en) 2008-07-03
AU2007275561A1 (en) 2008-01-24
RU2009106041A (ru) 2010-08-27
EP2068941A2 (en) 2009-06-17
US20120015053A1 (en) 2012-01-19
RU2469742C2 (ru) 2012-12-20
WO2008011173A2 (en) 2008-01-24
EP2438915A1 (en) 2012-04-11
CA2657915A1 (en) 2008-01-24
EP2068941A4 (en) 2009-09-30
RU2012137517A (ru) 2014-03-10
IL196480A0 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
AU2007275561B2 (en) Improvement of arginase levels/activity
US20190269715A1 (en) Compositions and method of use of a-type procyanidins
US7115656B2 (en) Compositions for, and methods of, anti-platelet therapy
KR20030005280A (ko) 혈관의 건강을 개선하기 위한 조성물과 방법
JP2009501161A (ja) 血管系の健康改善に有用な熱処理されたカカオ製品
JP6149290B2 (ja) 末梢血管の血管拡張の誘導
US20220387464A1 (en) Inositol phosphate-containing composition
US20090004290A1 (en) Red yeast rice compound for cancer chemoprevention
US20050277600A1 (en) Compositions and methods of use of dimer digallates
US20070004652A1 (en) Treatment of occlusive thrombosis
US20090286869A1 (en) Flavanols and B-Type Procyanidins and Inflammation
WO2007084648A2 (en) Mixed 4→6 procyanidin dimers and their use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)